| . | 2000–04 . | 2005–09 . | 2010–14 . | 2015–20 . | Total . |
|---|---|---|---|---|---|
| Patients, no (%) | 184 416 (35.3) | 162 907 (31.2) | 96 172 (18.4) | 79 185 (15.1) | 522 680 (100) |
| Age, years, median (IQR) | 68.6 (59.5, 77.2) | 65.7 (58.0, 74.5) | 65.9 (57.4, 73.9) | 66.0 (57.0, 73.1) | 66.7 (58.3, 75.2) |
| Male sex, no (%) | 88 390 (47.9) | 81 103 (49.8) | 48 554 (50.5) | 43 105 (54.4) | 261 152 (50.0) |
| Cardiovascular risk factors, no (%) | |||||
| Diabetes | 25 297 (13.7) | 25 943 (15.9) | 13 740 (14.3) | 10 937 (13.8) | 75 917 (14.5) |
| Hypertension | 64 973 (35.2) | 66 072 (40.6) | 39 551 (41.1) | 30 620 (38.7) | 201 216 (38.5) |
| Hyper-cholesterolemia | 26 739 (14.5) | 61 048 (37.5) | 41 844 (43.5) | 37 767 (47.7) | 167 398 (32.0) |
| COPD | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| ≥1 cardiovascular risk factor | 95 006 (51.5) | 106 022 (65.1) | 65 232 (67.8) | 54 427 (68.7) | 320 687 (61.4) |
| Bleeding risk factors, no (%) | |||||
| Prior bleeding event | 16 002 (8.7) | 16 926 (10.4) | 12 218 (12.7) | 11 474 (14.5) | 56 620 (10.8) |
| Recent bleeding event | 10 236 (5.6) | 8806 (5.4) | 5610 (5.8) | 4689 (5.9) | 29 341 (5.6) |
| Prior peptic ulcer | 8283 (4.5) | 7080 (4.3) | 4139 (4.3) | 2941 (3.7) | 22 443 (4.3) |
| Liver disease | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| Chronic kidney disease | 4012 (2.2) | 3370 (2.1) | 2528 (2.6) | 2656 (3.4) | 12 566 (2.4) |
| ≥ 1 bleeding risk factor | 26 197 (14.2) | 25 739 (15.8) | 17 812 (18.5) | 16 407 (20.7) | 86 155 (16.5) |
| Aspirin dose, no (%) | |||||
| 75 mg | 87 058 (47.2) | 136 720 (83.9) | 89 681 (93.3) | 75 332 (95.1) | 388 791 (74.4) |
| 100 mg | 32 713 (17.7) | 9688 (5.9) | 2394 (2.5) | 1185 (1.5) | 45 980 (8.8) |
| 150 mg | 64 645 (35.1) | 16 499 (10.1) | 4097 (4.3) | 2688 (3.4) | 87 909 (16.8) |
| Medications prescribed 1–180 days prior to aspirin prescription, no (%) | |||||
| PPI | 13 559 (7.4) | 17 674 (10.8) | 14 533 (15.1) | 13 720 (17.3) | 59 486 (11.4) |
| NSAID | 35 816 (19.4) | 34 889 (21.4) | 17 985 (18.7) | 12 087 (15.3) | 100 777 (19.3) |
| Glucocorticoids | 9524 (5.2) | 7768 (4.8) | 4878 (5.1) | 4016 (5.1) | 26 186 (5.0) |
| Medications prescribed 1–180 days after aspirin prescription, no (%) | |||||
| PPI | 18 130 (9.8) | 23 392 (14.4) | 18 726 (19.5) | 17 900 (22.6) | 78 148 (15.0) |
| NSAID | 35 025 (19.0) | 31 478 (19.3) | 15 229 (15.8) | 9655 (12.2) | 91 387 (17.5) |
| Glucocorticoids | 9892 (5.4) | 7857 (4.8) | 5034 (5.2) | 4104 (5.2) | 26 887 (5.1) |
| . | 2000–04 . | 2005–09 . | 2010–14 . | 2015–20 . | Total . |
|---|---|---|---|---|---|
| Patients, no (%) | 184 416 (35.3) | 162 907 (31.2) | 96 172 (18.4) | 79 185 (15.1) | 522 680 (100) |
| Age, years, median (IQR) | 68.6 (59.5, 77.2) | 65.7 (58.0, 74.5) | 65.9 (57.4, 73.9) | 66.0 (57.0, 73.1) | 66.7 (58.3, 75.2) |
| Male sex, no (%) | 88 390 (47.9) | 81 103 (49.8) | 48 554 (50.5) | 43 105 (54.4) | 261 152 (50.0) |
| Cardiovascular risk factors, no (%) | |||||
| Diabetes | 25 297 (13.7) | 25 943 (15.9) | 13 740 (14.3) | 10 937 (13.8) | 75 917 (14.5) |
| Hypertension | 64 973 (35.2) | 66 072 (40.6) | 39 551 (41.1) | 30 620 (38.7) | 201 216 (38.5) |
| Hyper-cholesterolemia | 26 739 (14.5) | 61 048 (37.5) | 41 844 (43.5) | 37 767 (47.7) | 167 398 (32.0) |
| COPD | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| ≥1 cardiovascular risk factor | 95 006 (51.5) | 106 022 (65.1) | 65 232 (67.8) | 54 427 (68.7) | 320 687 (61.4) |
| Bleeding risk factors, no (%) | |||||
| Prior bleeding event | 16 002 (8.7) | 16 926 (10.4) | 12 218 (12.7) | 11 474 (14.5) | 56 620 (10.8) |
| Recent bleeding event | 10 236 (5.6) | 8806 (5.4) | 5610 (5.8) | 4689 (5.9) | 29 341 (5.6) |
| Prior peptic ulcer | 8283 (4.5) | 7080 (4.3) | 4139 (4.3) | 2941 (3.7) | 22 443 (4.3) |
| Liver disease | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| Chronic kidney disease | 4012 (2.2) | 3370 (2.1) | 2528 (2.6) | 2656 (3.4) | 12 566 (2.4) |
| ≥ 1 bleeding risk factor | 26 197 (14.2) | 25 739 (15.8) | 17 812 (18.5) | 16 407 (20.7) | 86 155 (16.5) |
| Aspirin dose, no (%) | |||||
| 75 mg | 87 058 (47.2) | 136 720 (83.9) | 89 681 (93.3) | 75 332 (95.1) | 388 791 (74.4) |
| 100 mg | 32 713 (17.7) | 9688 (5.9) | 2394 (2.5) | 1185 (1.5) | 45 980 (8.8) |
| 150 mg | 64 645 (35.1) | 16 499 (10.1) | 4097 (4.3) | 2688 (3.4) | 87 909 (16.8) |
| Medications prescribed 1–180 days prior to aspirin prescription, no (%) | |||||
| PPI | 13 559 (7.4) | 17 674 (10.8) | 14 533 (15.1) | 13 720 (17.3) | 59 486 (11.4) |
| NSAID | 35 816 (19.4) | 34 889 (21.4) | 17 985 (18.7) | 12 087 (15.3) | 100 777 (19.3) |
| Glucocorticoids | 9524 (5.2) | 7768 (4.8) | 4878 (5.1) | 4016 (5.1) | 26 186 (5.0) |
| Medications prescribed 1–180 days after aspirin prescription, no (%) | |||||
| PPI | 18 130 (9.8) | 23 392 (14.4) | 18 726 (19.5) | 17 900 (22.6) | 78 148 (15.0) |
| NSAID | 35 025 (19.0) | 31 478 (19.3) | 15 229 (15.8) | 9655 (12.2) | 91 387 (17.5) |
| Glucocorticoids | 9892 (5.4) | 7857 (4.8) | 5034 (5.2) | 4104 (5.2) | 26 887 (5.1) |
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; IQR, interquartile range, NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitors.
| . | 2000–04 . | 2005–09 . | 2010–14 . | 2015–20 . | Total . |
|---|---|---|---|---|---|
| Patients, no (%) | 184 416 (35.3) | 162 907 (31.2) | 96 172 (18.4) | 79 185 (15.1) | 522 680 (100) |
| Age, years, median (IQR) | 68.6 (59.5, 77.2) | 65.7 (58.0, 74.5) | 65.9 (57.4, 73.9) | 66.0 (57.0, 73.1) | 66.7 (58.3, 75.2) |
| Male sex, no (%) | 88 390 (47.9) | 81 103 (49.8) | 48 554 (50.5) | 43 105 (54.4) | 261 152 (50.0) |
| Cardiovascular risk factors, no (%) | |||||
| Diabetes | 25 297 (13.7) | 25 943 (15.9) | 13 740 (14.3) | 10 937 (13.8) | 75 917 (14.5) |
| Hypertension | 64 973 (35.2) | 66 072 (40.6) | 39 551 (41.1) | 30 620 (38.7) | 201 216 (38.5) |
| Hyper-cholesterolemia | 26 739 (14.5) | 61 048 (37.5) | 41 844 (43.5) | 37 767 (47.7) | 167 398 (32.0) |
| COPD | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| ≥1 cardiovascular risk factor | 95 006 (51.5) | 106 022 (65.1) | 65 232 (67.8) | 54 427 (68.7) | 320 687 (61.4) |
| Bleeding risk factors, no (%) | |||||
| Prior bleeding event | 16 002 (8.7) | 16 926 (10.4) | 12 218 (12.7) | 11 474 (14.5) | 56 620 (10.8) |
| Recent bleeding event | 10 236 (5.6) | 8806 (5.4) | 5610 (5.8) | 4689 (5.9) | 29 341 (5.6) |
| Prior peptic ulcer | 8283 (4.5) | 7080 (4.3) | 4139 (4.3) | 2941 (3.7) | 22 443 (4.3) |
| Liver disease | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| Chronic kidney disease | 4012 (2.2) | 3370 (2.1) | 2528 (2.6) | 2656 (3.4) | 12 566 (2.4) |
| ≥ 1 bleeding risk factor | 26 197 (14.2) | 25 739 (15.8) | 17 812 (18.5) | 16 407 (20.7) | 86 155 (16.5) |
| Aspirin dose, no (%) | |||||
| 75 mg | 87 058 (47.2) | 136 720 (83.9) | 89 681 (93.3) | 75 332 (95.1) | 388 791 (74.4) |
| 100 mg | 32 713 (17.7) | 9688 (5.9) | 2394 (2.5) | 1185 (1.5) | 45 980 (8.8) |
| 150 mg | 64 645 (35.1) | 16 499 (10.1) | 4097 (4.3) | 2688 (3.4) | 87 909 (16.8) |
| Medications prescribed 1–180 days prior to aspirin prescription, no (%) | |||||
| PPI | 13 559 (7.4) | 17 674 (10.8) | 14 533 (15.1) | 13 720 (17.3) | 59 486 (11.4) |
| NSAID | 35 816 (19.4) | 34 889 (21.4) | 17 985 (18.7) | 12 087 (15.3) | 100 777 (19.3) |
| Glucocorticoids | 9524 (5.2) | 7768 (4.8) | 4878 (5.1) | 4016 (5.1) | 26 186 (5.0) |
| Medications prescribed 1–180 days after aspirin prescription, no (%) | |||||
| PPI | 18 130 (9.8) | 23 392 (14.4) | 18 726 (19.5) | 17 900 (22.6) | 78 148 (15.0) |
| NSAID | 35 025 (19.0) | 31 478 (19.3) | 15 229 (15.8) | 9655 (12.2) | 91 387 (17.5) |
| Glucocorticoids | 9892 (5.4) | 7857 (4.8) | 5034 (5.2) | 4104 (5.2) | 26 887 (5.1) |
| . | 2000–04 . | 2005–09 . | 2010–14 . | 2015–20 . | Total . |
|---|---|---|---|---|---|
| Patients, no (%) | 184 416 (35.3) | 162 907 (31.2) | 96 172 (18.4) | 79 185 (15.1) | 522 680 (100) |
| Age, years, median (IQR) | 68.6 (59.5, 77.2) | 65.7 (58.0, 74.5) | 65.9 (57.4, 73.9) | 66.0 (57.0, 73.1) | 66.7 (58.3, 75.2) |
| Male sex, no (%) | 88 390 (47.9) | 81 103 (49.8) | 48 554 (50.5) | 43 105 (54.4) | 261 152 (50.0) |
| Cardiovascular risk factors, no (%) | |||||
| Diabetes | 25 297 (13.7) | 25 943 (15.9) | 13 740 (14.3) | 10 937 (13.8) | 75 917 (14.5) |
| Hypertension | 64 973 (35.2) | 66 072 (40.6) | 39 551 (41.1) | 30 620 (38.7) | 201 216 (38.5) |
| Hyper-cholesterolemia | 26 739 (14.5) | 61 048 (37.5) | 41 844 (43.5) | 37 767 (47.7) | 167 398 (32.0) |
| COPD | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| ≥1 cardiovascular risk factor | 95 006 (51.5) | 106 022 (65.1) | 65 232 (67.8) | 54 427 (68.7) | 320 687 (61.4) |
| Bleeding risk factors, no (%) | |||||
| Prior bleeding event | 16 002 (8.7) | 16 926 (10.4) | 12 218 (12.7) | 11 474 (14.5) | 56 620 (10.8) |
| Recent bleeding event | 10 236 (5.6) | 8806 (5.4) | 5610 (5.8) | 4689 (5.9) | 29 341 (5.6) |
| Prior peptic ulcer | 8283 (4.5) | 7080 (4.3) | 4139 (4.3) | 2941 (3.7) | 22 443 (4.3) |
| Liver disease | 2498 (1.4) | 2825 (1.7) | 1992 (2.1) | 2026 (2.6) | 9341 (1.8) |
| Chronic kidney disease | 4012 (2.2) | 3370 (2.1) | 2528 (2.6) | 2656 (3.4) | 12 566 (2.4) |
| ≥ 1 bleeding risk factor | 26 197 (14.2) | 25 739 (15.8) | 17 812 (18.5) | 16 407 (20.7) | 86 155 (16.5) |
| Aspirin dose, no (%) | |||||
| 75 mg | 87 058 (47.2) | 136 720 (83.9) | 89 681 (93.3) | 75 332 (95.1) | 388 791 (74.4) |
| 100 mg | 32 713 (17.7) | 9688 (5.9) | 2394 (2.5) | 1185 (1.5) | 45 980 (8.8) |
| 150 mg | 64 645 (35.1) | 16 499 (10.1) | 4097 (4.3) | 2688 (3.4) | 87 909 (16.8) |
| Medications prescribed 1–180 days prior to aspirin prescription, no (%) | |||||
| PPI | 13 559 (7.4) | 17 674 (10.8) | 14 533 (15.1) | 13 720 (17.3) | 59 486 (11.4) |
| NSAID | 35 816 (19.4) | 34 889 (21.4) | 17 985 (18.7) | 12 087 (15.3) | 100 777 (19.3) |
| Glucocorticoids | 9524 (5.2) | 7768 (4.8) | 4878 (5.1) | 4016 (5.1) | 26 186 (5.0) |
| Medications prescribed 1–180 days after aspirin prescription, no (%) | |||||
| PPI | 18 130 (9.8) | 23 392 (14.4) | 18 726 (19.5) | 17 900 (22.6) | 78 148 (15.0) |
| NSAID | 35 025 (19.0) | 31 478 (19.3) | 15 229 (15.8) | 9655 (12.2) | 91 387 (17.5) |
| Glucocorticoids | 9892 (5.4) | 7857 (4.8) | 5034 (5.2) | 4104 (5.2) | 26 887 (5.1) |
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; IQR, interquartile range, NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitors.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
